



Łomianki, 20.09.2017

*Purchaser:*

**Celon Pharma S.A.**

Mokra 41A

05-092 Łomianki / Kielpin

tel.: +48 22 751 74 78

fax: +48 22 751 74 77

e-mail:  [paulina.gruszka@celonpharma.com](mailto:paulina.gruszka@celonpharma.com)

National Court Register number (KRS ): 0000437778

Tax ID number (NIP): 118 - 16 - 42 - 061

### **REQUEST FOR QUOTATION (RfQ) no. 21/2017/M/GATE**

In relation to the project called "Preclinical and clinical development of an innovative GPR40 agonist in type II diabetes" under the "Smart Growth Operational Programme 2014-2020" (hereinafter "the Project"), we hereby request your quotation for:

**Subcontracting: Selectivity screen against a broad panel of receptors and proteins that may mediate off-targets effects – *in vitro***

- The screen needs to be performed *in vitro*, as a functional assay (in cell lines or on the receptors)
- The results need to be submitted as percent of inhibition or activation compared to the control
- The screen should include at least 44 selected targets, recommended by 4 major pharmaceutical companies according the publication (Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. "Reducing safety-related drug attrition: the use of *in vitro* pharmacological profiling; Nature Reviews. Drug Discovery (2012), 11(12), 909–22. <http://doi.org/10.1038/nrd3845> page 913-915 (tabela 1).)
- The assay should be conducted in duplicates or triplicates for a single target protein, in single-pointed concentration of the compound.
- Expected turnover time: 30 days for executing a given order (starting from the moment of receiving the compound(s) by contractor and ending at the moment of the final report delivery)
- On demand, the contractor should present raw data from the experiment.

The experiment is planned for 1 compounds. The order reserves the right to change the number of testing compounds.

The study will be ordered between October 2017 and December 2017 based on a purchase order prepared by client.

**Celon Pharma S.A.**

Biuro główne: Ogrodowa 2A, Kielpin  
05-092 Łomianki, Polska  
telefon: +48 22 751 59 33  
fax: +48 22 751 44 58  
e-mail: [info@celonpharma.com](mailto:info@celonpharma.com)

Organ rejestrujący: Sąd Rejonowy dla Miasta Stołecznego Warszawy w Warszawie  
XIV Wydział Gospodarczy Krajowego Rejestru Sądowego  
Prezes Zarządu: Maciej Wieczorek  
KRS: 0000437778  
Kapitał zakładowy: 4 500 000 PLN  
NIP: 118 – 16 – 42 – 061  
[www.celonpharma.com](http://www.celonpharma.com)

**Requirements to be met by bidders:**

Bidder have to deliver a statement concerning compliance with the following criterions. Lack of such statement will result in excluding Bidder's offer from tender:

1. The Bidder should have the necessary experience and technical and laboratory infrastructure to deliver the subject of the order.
2. The Bidder should possess scientific personnel specialized in areas related to the subject of this request.
3. The Bidder should hold all licenses required by law to deliver the subject of the order.
4. The Bidder's financial and economic position should ensure proper realization of the ordered study.

**Address and date for submitting the bids:**

1. Bids must be submitted by electronic mail to [paulina.gruszka@celonpharma.com](mailto:paulina.gruszka@celonpharma.com)
2. Bid must be submitted by the **4<sup>th</sup> of October 2017** at the latest.
3. Bids submitted after the aforementioned date will not be considered.
4. Bids will be evaluated at the Purchaser's office within 7 days from submission deadline.
5. The final decision will be communicated to all Bidders by electronic mail within 7 days from submission deadline.
6. For further information on the Project, please contact Katarzyna Bazydło, e-mail: [katarzyna.bazydlo@celonpharma.com](mailto:katarzyna.bazydlo@celonpharma.com)

**Presentation of the bids:**

1. Each Bidder may submit only one bid.
2. The bid must contain the date of preparation, the Bidder's address, telephone number, email address, tax ID number.
3. **The bid must be valid until the end of the year 2017.**
4. The bid must contain:
  - if submitted by a Bidder operating in Poland, the gross and net bid price and due VAT offered for delivery of the subject of the order on accordance with the requirements set forth herein,
  - if submitted by a Bidder operating outside Poland, the net bid price and information that not VAT or other taxes have been included in the price quotation.
5. The bid should contain the RfQ no. in the title. The RfQ no. must also appear in the titles of invoices.

**Note:**

1. **This project is currently under evaluation by The National Centre for Research and Development as a part of funding competition therefore the Purchaser reserves the right to cancel the order in case of non-co-financing.**
2. The Purchaser will place the order with the bidder whose bid meets all the requirements set forth in this RfQ and is deemed the best relative to the selection criteria set forth herein.

3. The Purchaser reserves the right to close the bidding process without selecting the successful Bidder. In such case the purchaser doesn't need to specify its reasons for doing so.
4. In the course of evaluation and assessment of the bids, the Purchaser may request that the bidders provide clarifications regarding their bids.
5. The bidder may alter or withdraw its offer before the submission deadline.
6. Bids submitted past the submission deadline will not be considered.
7. Bids that do not meet the formal requirements set forth herein will not be considered.
8. The Purchaser does not accept variant bids.
9. The Purchaser does not accept partial bids.
10. The Purchaser permits rejecting bids whose essential content clearly raises reasonable doubts.

**The quote will be selected based on the following criteria:**

1. Price – (max. 40 points – this is 40% of the maximum number of points to gain). The points will be awarded as follows: The lowest offered price will be considered 100% and awarded maximal number of points (40 points). The points for consequent offers will be given based on the formula:

$$\frac{Price_{lowest}}{Price_{service}} \times 40 pts$$

where:

Price<sub>lowest</sub> – lowest price amongst offers.

Price<sub>service</sub> – price proposed in evaluated offer.

2. Quality – (maximally a total of 30 points – this is 30% of the maximum number of points to gain). The points will be given based on the mentioned publication Bowes et al. Inhibition determined for each target will be awarded with 1 point (max 44). The maximal points number to achieve is 30 and will be given based on the formula:

$$\frac{\text{number of targets' inh. determined}}{44} \times 30 pts$$

3. Declared time of delivery of the results – (max. 25 points – this is 25% of the maximum number of points to gain). 25 points will be given to the Client who will provide the results within 30 days from receiving the compounds. 16 points will be given to the Client who will provide the results within 30-45 days from receiving the compounds. 8 points will be given to the Client who will provide the results within 45-60 days from receiving the compounds. 0 points will be given to the Client who will provide the results in more than 60 days from receiving the compounds.
4. Sharing the raw data - (max. 5 points – this is 5 % of the maximum number of points to gain) 5 points will be given for the on-demand sharing of raw data from experiment.
5. Total scoring will be considered as a sum of Price, Quality, Declared time of delivery of the results and Sharing the raw data (100 points maximally to gain).